FDA Approves Dual-Energy Catheter Ablation Platform - Summary - MDSpire

FDA Approves Dual-Energy Catheter Ablation Platform

The platform integrates with the CARTO ecosystem and enables physicians to use either pulsed field or radiofrequency energy based on patient anatomy and case complexity.

  • By

  • Kathryn Wighton

  • July 8, 2026

  • 2 min

Share

Objective:

To announce the FDA approval of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform for catheter ablation.

Approach:
  • Platform Overview: The platform allows delivery of both pulsed field and radiofrequency energy through a single catheter.
  • Integration: It is integrated with the CARTO ecosystem, which includes mapping, imaging, and pulsed field index guidance.
Key Findings:
  • The platform is built on the THERMOCOOL SMARTTOUCH SF catheter platform, used in over one million US patients.
  • It enables precise contact force delivery of energy tailored to patient anatomy and case complexity.
  • First US procedures are expected to begin this summer as part of a phased rollout.
Interpretation:

The platform provides electrophysiologists with the flexibility to choose between RF and PF energy based on procedural needs.

Limitations:
  • Dhanunjaya Lakkireddy, MD, FHRS, MBA, is a consultant for Johnson & Johnson and was not compensated for his contribution to the announcement.
Conclusion:

The Dual Energy THERMOCOOL SMARTTOUCH SF Platform aims to enhance procedural confidence and adaptability in complex cases.

Sources:

Original Source(s)

FDA Approves Dual-Energy Catheter Ablation Platform

  • by Kathryn Wighton

  • July 8, 2026

Related Content

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.

Low-Dose Oral Minoxidil Monitoring Questioned

A retrospective hair clinic study found stable blood pressure, heart rate, weight, and laboratory measures during follow-up of up to 30 months.

Clinical and genetic analysis of pediatric catecholaminergic polymorphic ventricular tachycardia: focus on sinus bradycardia and neurodevelopmental disorders